LiveSpo
Our Investments

LiveSpo

Fund

Mekong Enterprise Fund IV

Deal Leader

Lai Ha Thu

Website

Dr. Nguyen Hoa Anh – Founder of LiveSpo

A Future Without Antibiotics

LiveSpo is a pioneering Vietnamese biotechnology company founded in by Dr. Nguyen Hoa Anh and his colleagues, specializing in liquid spore-based probiotics. Unlike traditional probiotics, LiveSpo’s products use  spore-forming bacteria in liquid form, which are more resilient to stomach acid and deliver higher efficacy.

The company’s mission is to create “A Future Without Antibiotics” with applications across digestive health, respiratory infections, skincare, and maternal care. 

The company has published multiple peer-reviewed studies in Nature Scientific Reports and has conducted clinical trials listed on ClinicalTrials.gov, validating the safety and efficacy of its innovations.

 

LiveSpo’s product portfolio includes:

LiveSpo NAVAX

Hero product of LiveSpo which is a specialized spore probiotic nasal spray - support both treatment and prevention of respiratory infections due to virus and bacteria.

A peer-reviewed study published in Nature Scientific Reports demonstrated that LiveSpo NAVAX:


  • Reduced viral loads of Respiratory Syncytial Virus (RSV) and influenza by up to 600 times

  • Was 50–70 times more effective than physiological saline after just 2–3 days of use

  • Shortened recovery time and enhanced immune response in children


These findings confirm NAVAX’s potential as a safe, fast-acting, and effective probiotic-based therapy for pediatric respiratory infections.

LiveSpo Navax Products

A liquid spore-based probiotic supplement to prevent of digestive disorders caused by the side effects of antibiotics.

A study published in Nature Scientific Reports demonstrated that LiveSpo CLAUSY:


  • Accelerated recovery from persistent diarrhea by 3 days

  • Improved gastrointestinal symptoms more effectively than standard treatments

  • Enhanced immune response, offering a natural and safe alternative to conventional therapies

These findings highlight CLAUSY’s potential as a fast-acting, probiotic-based solution for managing antibiotic-associated digestive issues in pediatric care.

LiveSpo Clausy product

A liquid spore-based probiotic supplement as supportive treatment for diarrhea. Stop diarrhea in 30 minutes.

A liquid spore-based probiotic supplement designed to support the treatment of Ulcerative Colitis (UC) and Irritable Bowel Syndrome (IBS)

Currently undergoing clinical evaluation, LiveSpo COLON is being studied for its ability to:


  • Reduce inflammation and improve gut microbiota balance

  • Alleviate symptoms such as abdominal pain, bloating, and irregular bowel movements

  • Serve as a natural, adjunctive therapy alongside conventional treatments

The ongoing clinical trial aims to validate its efficacy and safety as a supportive probiotic-based solution for patients with UC and IBS.

LiveSpo Colon

Targeted solutions for inflammation, fungus itching, maternal health, and acne.

LiveSpo Pregmom product
LiveSpo Navax Products
LiveSpo Clausy product
LiveSpo Colon
LiveSpo Pregmom product

Transformation into a Global Biotech Brand

Since receiving investment from Mekong Capital, LiveSpo has rapidly evolved from a science-driven startup into a globally ambitious biotech brand. The company has achieved several key milestones that reflect its accelerated growth and international positioning:

LiveSpo Colon at Pharmacity

Domestic Expansion

LiveSpo is strengthening its presence across Vietnam by partnering with top pharmaceutical chains such as Long Châu, Pharmacity, and An Khang. These partnerships have significantly increased consumer access to LiveSpo’s clinically validated spore-based probiotic products. Since Mekong Capital’s investment, the number of pharmacies carrying LiveSpo products has quadrupled to nearly 4,700 at the end of September 2025.

 

Export & E-commerce Growth

LiveSpo has expanded its footprint in the U.S. and European markets through Amazon and strategic distribution partnerships, reinforcing its position as a pioneering Vietnamese biotech brand with global reach.

Industry Leadership

LiveSpo’s international expansion is guided by a highly experienced Board of Directors and strategic advisors:

Ben McHarg

Co-founder and former CEO of Life-Space Group, one of Australia’s leading probiotic companies. He led the company through its acquisition by Chinese supplement giant BY-HEALTH in 2018, in a deal valued at approximately USD 690–700 million.

 

Jorge Martin Martinez

Former Country Head of DKSH Vietnam and CFO of DKSH Indochina. DKSH is a publicly listed Swiss group specializing in marketing, sales, distribution, and sourcing across Consumer Goods, Healthcare, Specialty Chemicals, and Technology sectors.

Isabelle Ducellier

Former CEO of BioGaia AB, a globally recognized Swedish probiotics company. Under her leadership, BioGaia expanded to over 100 countries. Her deep expertise in global consumer health is expected to accelerate LiveSpo’s strategic growth and international footprint.

Global Recognition & Scientific Validation

LiveSpo’s flagship product, LiveSpo NAVAX, has gained international attention through three separate clinical trials of its flagship product, LiveSpo NAVAX, have been featured in Journal Nature, showcasing its ability to reduce RSV, pneumonia, and influenza viral loads by up to 600 times—a breakthrough in pediatric respiratory care.

  1. Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection
  2. Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics
  3. Nasal-spraying Bacillus spore probiotics for pneumonia in children with respiratory syncytial virus and bacterial co-infections: a randomized clinical trial
Gene Solutions

Gene Solutions

Next Investment